Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Inclusion Criteria
- There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT [all sites])
- Standard risk 1: Patient must be < 11 years of age at enrollment
- Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment
- Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with metastatic germ cell tumor (stage II or higher); histologic confirmation of a primary extracranial germ cell tumor in any of the categories outlined below is required of all patients at enrollment except for those who were initially diagnosed with stage I non-seminoma malignant GCT and later recur during observation post surgery off study; for these patients, if elevated tumor markers rise to > 5 x upper limit of normal (ULN) on at least 2 measurements taken at least 1 week apart, a diagnostic biopsy is not required for enrollment
- Low risk stage I immature teratoma (IT); site: ovarian; stage: Children's Oncology Group (COG) stage I, Federation of Gynecology and Obstetrics (FIGO) stage IA and IB; grade: 2 or 3; histology: pure immature teratoma (may contain microscopic foci of yolk sac tumor), mixed immature and mature teratoma, (no pathological evidence of MGCT); tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; all ages
- Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA, IB and IS; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages
- Low risk stage I seminoma-MGCT; site: testicular; stage: COG stage I; AJCC testicular stage IA IB, and IS; histology: must contain at least one of the following: may contain immature/mature teratoma; may NOT contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; all ages
- Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC, FIGO stage II-IV (International Germ Cell Consensus Classification [IGCCC] criteria DO NOT apply); histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) < 11
- Standard risk 2 (SR2) * Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25 * Site: testicular; stage: COG stage II-IV, AJCC stage II, III, IGCCC good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; tumor markers: must be IGCCC good risk; post op: alpha-FP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL and lactate dehydrogenase (LDH) < 3.0 x normal; age (years) >= 11 and < 25 * Site: extragonadal; stage: COG stage II; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25
- Notes: * IGCCC criteria only apply to SR2 patients with a testicular primary tumor * Use post-op tumor marker levels to determine IGCCC risk group * Stage 1 seminoma patients are not eligible for the standard risk arms of the study * For the low risk stage I non-seminoma MGCT and the standard risk arms, components of yolk sac tumor, embryonal carcinoma, or choriocarcinoma can be mixed with other forms of GCT, such as seminoma or mature or immature teratoma; if yolk sac tumor is the only malignant component present, then it must be deemed by the pathologist to be greater than a “microscopic component” of yolk sac tumor
- Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, 2 or 3; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
- Organ function requirements apply ONLY to patients who will receive chemotherapy (SR1 and SR2 patients)
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2
- A serum creatinine based on age/gender as follows: (mg/dL) * 1 month to < 6 months male: 0.4 female: 0.4 * 6 months to < 1 year male: 0.5 female: 0.5 * 1 to < 2 years male: 0.6 female: 0.6 * 2 to < 6 years male: 0.8 female: 0.8 * 6 to < 10 years male: 1 female: 1 * 10 to < 13 years male: 1.2 female: 1.2 * 13 to < 16 years: male: 1.5 female: 1.4 * >= 16 years male: 1.7 female: 1.4
- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age (for the purpose of this study, the ULN for SGPT is 45 U/L)
- Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3
- Platelet count >= 100,000/mm^3
- Patients enrolling on the standard risk arms must be medically fit to receive protocol treatment and with no contraindications to protocol treatment
- Eligibility criteria to participate in the pilot study of the AYA-Hears instrument (patient reported outcomes [PROs] of ototoxicity) Note: participants in group 1 will not receive AGCT1531 protocol-directed therapy; all other AYA-HEARS patients must be enrolled on the AGCT1531 SR2 arm in order to participate
- >= 11 and < 25 years old at enrollment
- Able to fluently speak and read English
- Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor
- Followed for cancer or survivorship care at one of the following institutions: * Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center * Dana Farber/Harvard Cancer Center * Hospital for Sick Children * Children’s Hospital of Eastern Ontario * Oregon Health and Science University * Seattle Children’s Hospital * Yale University
Exclusion Criteria
- Patients with any diagnoses not listed including: * Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection) * Pure dysgerminoma * Pure mature teratoma * Pure immature teratoma COG stage I, grade I * Pure immature teratoma COG stage I, grade 2,3 with alpha-fetoprotein (AFP) >= 1000 ng/mL * Pure immature teratoma COG stage II - IV or FIGO stage IC to IV * "Poor risk" GCT (age >= 11 years old and COG stage IV ovarian, COG stage III or IV EG, or IGCCC intermediate or poor risk testicular), or * Primary central nervous system (CNS) germ cell tumor * Germ cell tumor with somatic malignant transformation * Spermatocytic seminoma
- Patients must have had no prior systemic therapy for the current cancer diagnosis
- Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain [stage IV disease] would be considered poor risk and therefore not eligible for this trial)
- Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin, are ineligible for the standard risk arms of the trial
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])
- Lactating females who plan to breastfeed their infants; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])
Alabama
Birmingham
Mobile
Alaska
Anchorage
Arizona
Kingman
Mesa
Phoenix
Tucson
Arkansas
Hot Springs
Little Rock
California
Anaheim
Arroyo Grande
Bellflower
Burbank
Downey
Duarte
Fontana
Loma Linda
Long Beach
Los Angeles
Madera
Newport Beach
Oakland
Orange
Palo Alto
Roseville
Sacramento
San Diego
San Francisco
San Luis Obispo
Santa Clara
Santa Maria
Torrance
Colorado
Aurora
Colorado Springs
Denver
Durango
Fort Collins
Golden
Greeley
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Connecticut
Hartford
New Haven
Delaware
Wilmington
District of Columbia
Washington
Florida
Fort Lauderdale
Fort Myers
Gainesville
Hollywood
Jacksonville
Miami
Orlando
Pensacola
Saint Petersburg
Tampa
West Palm Beach
Georgia
Atlanta
Augusta
Macon
Savannah
Hawaii
Honolulu
Idaho
Boise
Fruitland
Meridian
Nampa
Twin Falls
Illinois
Aurora
Bloomington
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Dixon
Effingham
Eureka
Evanston
Galesburg
Glenview
Highland Park
Kewanee
Macomb
Mattoon
Maywood
O'Fallon
Oak Lawn
Ottawa
Park Ridge
Pekin
Peoria
Peru
Princeton
Skokie
Springfield
Swansea
Urbana
Yorkville
Indiana
Carmel
Evansville
Indianapolis
Newburgh
South Bend
Iowa
Clive
Council Bluffs
Creston
Des Moines
Iowa City
West Des Moines
Kentucky
Bardstown
Corbin
Lexington
London
Louisville
Shepherdsville
Louisiana
New Orleans
Maine
Bangor
Brewer
Portland
Scarborough
Maryland
Baltimore
Bethesda
Massachusetts
Boston
Worcester
Michigan
Ann Arbor
Battle Creek
Detroit
East Lansing
Escanaba
Flint
Grand Rapids
Kalamazoo
Muskegon
Niles
Port Huron
Reed City
Royal Oak
Saint Joseph
Traverse City
Wyoming
Minnesota
Duluth
Minneapolis
Rochester
Mississippi
Jackson
Missouri
Bonne Terre
Cape Girardeau
Farmington
Jefferson City
Kansas City
Saint Louis
Sainte Genevieve
Sullivan
Sunset Hills
Montana
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Lebanon
New Jersey
Hackensack
Morristown
New Brunswick
Newark
Paterson
New York
Albany
Bronx
Buffalo
Glens Falls
Mineola
New Hyde Park
New York
Rochester
Stony Brook
Syracuse
Valhalla
North Carolina
Asheville
Chapel Hill
Charlotte
Clinton
Durham
Goldsboro
Huntersville
Jacksonville
Matthews
Mooresville
Salisbury
Winston-Salem
North Dakota
Fargo
Ohio
Akron
Belpre
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Dublin
Grove City
Mansfield
Marietta
Marion
Mount Vernon
Newark
Portsmouth
Sylvania
Toledo
Westerville
Zanesville
Oklahoma
Lawton
Oklahoma City
Oregon
Bend
Clackamas
Coos Bay
Medford
Newberg
Portland
Pennsylvania
Abington
Allentown
Bethlehem
Danville
Hershey
Philadelphia
Pittsburgh
Willow Grove
Puerto Rico
Caguas
San Juan
Rhode Island
Providence
South Carolina
Boiling Springs
Charleston
Columbia
Gaffney
Greenville
Greer
Seneca
Spartanburg
Union
South Dakota
Sioux Falls
Tennessee
Chattanooga
Hixson
Knoxville
Memphis
Nashville
Ooltewah
Texas
Austin
Bryan
Corpus Christi
Dallas
El Paso
Fort Worth
Houston
Lubbock
San Antonio
Temple
Utah
Salt Lake City
Vermont
Berlin
Burlington
Virginia
Norfolk
Portsmouth
Richmond
Washington
Aberdeen
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Issaquah
Kennewick
Lacey
Lakewood
Longview
Poulsbo
Seattle
Shelton
Spokane
Spokane Valley
Tacoma
Vancouver
Walla Walla
Yelm
West Virginia
Bridgeport
Charleston
Martinsburg
Morgantown
Parkersburg
Wisconsin
Green Bay
Johnson Creek
Madison
Manitowoc
Marinette
Milwaukee
Oconto Falls
Sheboygan
Sturgeon Bay
Alberta
Calgary
Edmonton
British Columbia
Vancouver
Manitoba
Winnipeg
Newfoundland and Labrador
Saint John's
Nova Scotia
Halifax
Ontario
Hamilton
Kingston
London
Ottawa
Toronto
Quebec
Montreal
Quebec
Australia
Clayton
Hunter Regional Mail Centre
Parkville
Perth
Randwick
South Brisbane
Westmead
Japan
Chuo-ku
Higashi-ku
Hiroshima City
Kobe
Kyoto
Niigata
Nishinomiya, Hyogo
Osaka City
Saitama
Sendai
Shinjuku-ku
Tokyo
Tsukuba
Yokohama
New Zealand
Christchurch
Grafton
Saudi Arabia
Riyadh
PRIMARY OBJECTIVES:
I. To evaluate whether a strategy of complete surgical resection followed by surveillance can maintain an overall survival rate of at least 95.7% at two years for pediatric, adolescent and adult patients with stage I (low risk) malignant germ cell tumors, and at least 95% for patients with ovarian pure immature teratoma.
II. To compare the event-free survival of a carboplatin versus (vs.) cisplatin-based regimen in the treatment of pediatric, adolescent and young adult patients with standard risk non-seminomatous germ cell tumors.
IIa. To compare the event free survival (EFS) of a carboplatin-based regimen (carboplatin [C] etoposide [E] bleomycin [b]) vs. a cisplatin-based regimen (cisplatin [P]Eb) in children (less than 11 years in age) with standard risk germ cell tumors (GCT).
IIb. To compare the EFS of a carboplatin-based regimen (BEC) vs. a cisplatin-based regimen (BEP) in adolescents and young adults (ages 11 - < 25 years) with standard risk GCT.
SECONDARY OBJECTIVES:
I. To compare the incidence of ototoxicity in children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin-based chemotherapy.
II. To refine and validate a novel patient-reported measure of hearing outcomes for children, adolescents and young adults with standard risk germ cell tumors.
EXPLORATORY OBJECTIVES:
I. To prospectively determine the correlation of tumor marker decline (alpha-fetoprotein [FP] and beta-human chorionic gonadotropin [HCG]) with clinical outcome in low and standard risk germ cell tumor patients.
II. To compare self-reported peripheral neuropathy and other patient-reported outcomes between children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin based chemotherapy.
III. Assess the relationship between hearing loss as measured by audiometry with the effects of tinnitus as assessed on the Adolescent and Young Adult Hearing Screening (AYA-HEARS) instrument.
IV. To evaluate the prognostic significance of serum micro ribonucleic acid (miRNA)s in stage I testicular cancer (seminoma and non-seminoma) patients by collecting clinical data and serum specimens for future analysis.
OUTLINE:
Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma malignant germ cell tumors (MGCT)s undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician.
Patients with standard risk 1 are randomized into 1 of 2 arms.
ARM I (CEb): Patients receive bleomycin intravenously (IV) over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM II (PEb): Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Patients with standard risk 2 are randomized into 1 of 2 arms.
ARM III (BEC): Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
ARM IV (BEP): Patients receive bleomycin IV over 10 minutes on days 1, 8, 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 2 months for 12 months, every 3-6 months to 24 months, every 6 months for years 3-5, and then annually for up to 10 years.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Children's Oncology Group
Principal Investigator
A. Lindsay Frazier
- Primary ID AGCT1531
- Secondary IDs NCI-2017-00178
- Clinicaltrials.gov ID NCT03067181